These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11142690)

  • 1. Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients.
    Smorenburg CH; Seynaeve C; Bontenbal M; Planting AS; Sindermann H; Verweij J
    Anticancer Drugs; 2000 Nov; 11(10):825-8. PubMed ID: 11142690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.
    Terwogt JM; Mandjes IA; Sindermann H; Beijnen JH; ten Bokkel Huinink WW
    Br J Cancer; 1999 Mar; 79(7-8):1158-61. PubMed ID: 10098751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer.
    Leonard R; Hardy J; van Tienhoven G; Houston S; Simmonds P; David M; Mansi J
    J Clin Oncol; 2001 Nov; 19(21):4150-9. PubMed ID: 11689583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Miltefosine: new preparation. Solution for cutaneous application.
    Prescrire Int; 1998 Feb; 7(33):5-6. PubMed ID: 10183390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma.
    Clive S; Gardiner J; Leonard RC
    Cancer Chemother Pharmacol; 1999; 44 Suppl():S29-30. PubMed ID: 10602908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
    Unger C; Peukert M; Sindermann H; Hilgard P; Nagel G; Eibl H
    Cancer Treat Rev; 1990 Sep; 17(2-3):243-6. PubMed ID: 2272039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of cutaneous metastases of a squamous cell carcinoma of the leg with topical miltefosine].
    Mahieu-Renard L; Richard MA; Dales JP; Buscaylet S; Lagrassa S; Grob JJ
    Ann Dermatol Venereol; 2005 Apr; 132(4):346-8. PubMed ID: 15886562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer.
    Planting AS; Stoter G; Verweij J
    Eur J Cancer; 1993; 29A(4):518-9. PubMed ID: 8435202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [[Treatment with Miltex for metastatic skin lesions in breast cancer] ].
    Moĭseenko VM; Orlova RV; Ermakova NA; Protsenko SA
    Vopr Onkol; 2000; 46(5):600-3. PubMed ID: 11202195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma.
    Dumontet C; Thomas L; Bérard F; Gimonet JF; Coiffier B
    Bull Cancer; 2006 Nov; 93(11):E115-8. PubMed ID: 17145574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
    Unger C; Sindermann H; Peukert M; Hilgard P; Engel J; Eibl H
    Prog Exp Tumor Res; 1992; 34():153-9. PubMed ID: 1438798
    [No Abstract]   [Full Text] [Related]  

  • 12. [Multiple cutaneous plasmocytoma treated with topical applications of miltefosine].
    Viseux V; Schoenlaub P; Danhier S; Vilque JP; Plantin P
    Ann Dermatol Venereol; 2004 Feb; 131(2):204-5. PubMed ID: 15026752
    [No Abstract]   [Full Text] [Related]  

  • 13. Topical agents and dressings for fungating wounds.
    Adderley U; Smith R
    Cochrane Database Syst Rev; 2007 Apr; (2):CD003948. PubMed ID: 17443534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase 2 study of perifosine in advanced or metastatic breast cancer.
    Leighl NB; Dent S; Clemons M; Vandenberg TA; Tozer R; Warr DG; Crump RM; Hedley D; Pond GR; Dancey JE; Moore MJ
    Breast Cancer Res Treat; 2008 Mar; 108(1):87-92. PubMed ID: 17458693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I/II study.
    Dummer R; Krasovec M; Röger J; Sindermann H; Burg G
    J Am Acad Dermatol; 1993 Dec; 29(6):963-70. PubMed ID: 8245262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hexadecylphosphocholine (D 18506) in the topical treatment of skin metastases: a phase-I trial.
    Unger C; Eibl H; Breiser A; von Heyden HW; Engel J; Hilgard P; Sindermann H; Peukert M; Nagel GA
    Onkologie; 1988 Dec; 11(6):295-6. PubMed ID: 3071766
    [No Abstract]   [Full Text] [Related]  

  • 17. A phase II study of CI-973 [SP-4-3(R)]-1,1-cyclobutane-dicarboxylato (2-)] (2-methyl-1,4-butanediamine-N, N') platinum in patients with refractory advanced breast cancer.
    Theriault RL; Walters RS; Holmes FA; Esparza-Guerra L; Kowal C; Hortobagyi GN
    Cancer Chemother Pharmacol; 1996; 38(3):289-91. PubMed ID: 8646805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model.
    Van Bocxlaer K; Yardley V; Murdan S; Croft SL
    J Pharm Pharmacol; 2016 Jul; 68(7):862-72. PubMed ID: 27230300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study.
    Verweij J; Krzemieniecki K; Kok T; Poveda A; van Pottelsberghe C; van Glabbeke M; Mouridsen H
    Eur J Cancer; 1993; 29A(2):208-9. PubMed ID: 8422284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
    Aguiar MG; Silva DL; Nunan FA; Nunan EA; Fernandes AP; Ferreira LA
    J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.